ABSTRACT
Betatrophin is a newly characterized circulating hormone that is produced in tissues such as adipose tissue and liver and stimulates pancreatic beta-cell proliferation. The purpose of the current study was to examine circulating betatrophin levels in Iranian patients with type 2 diabetes mellitus (T2DM) and in normal controls. Seventy-five subjects were enrolled in this case-control study in the following two groups: T2DM patients (n=40) and a group of age-, sex-, and BMI-matched normal control subjects (n=35). Circulating betatrophin concentrations as well as the blood lipid profile, body mass index (BMI), fasting blood sugar (FBS), glycated hemoglobin (HbA1c), and insulin resistance were determined. Circulating betatrophin levels were significantly higher in patients with T2DM than in the normal subjects (4.79+/-1.53 ng/mL vs. 2.79+/-1.11 ng/mL respectively; p=0.001). Serum triacylglycerol and total cholesterol were also significantly higher in patients with T2DM than in the control group. In the patients with T2DM, serum betatrophin was positively correlated with age, FBS, TG, total cholesterol, and HbA1c. The results of this initial study in Iran have shown that circulating betatrophin levels are significantly increased in Iranian patients with T2DM compared with a control group. Additionally, it is postulated that betatrophin as a novel hormone may be involved in the generation of an atherogenic lipid profile.
Subject(s)
Humans , Adipose Tissue , Blood Glucose , Body Mass Index , Case-Control Studies , Cholesterol , Diabetes Mellitus , Diabetes Mellitus, Type 2 , Fasting , Glycated Hemoglobin , Insulin Resistance , Iran , Liver , TriglyceridesABSTRACT
Betatrophin is a newly characterized circulating hormone that is produced in tissues such as adipose tissue and liver and stimulates pancreatic beta-cell proliferation. The purpose of the current study was to examine circulating betatrophin levels in Iranian patients with type 2 diabetes mellitus (T2DM) and in normal controls. Seventy-five subjects were enrolled in this case-control study in the following two groups: T2DM patients (n=40) and a group of age-, sex-, and BMI-matched normal control subjects (n=35). Circulating betatrophin concentrations as well as the blood lipid profile, body mass index (BMI), fasting blood sugar (FBS), glycated hemoglobin (HbA1c), and insulin resistance were determined. Circulating betatrophin levels were significantly higher in patients with T2DM than in the normal subjects (4.79+/-1.53 ng/mL vs. 2.79+/-1.11 ng/mL respectively; p=0.001). Serum triacylglycerol and total cholesterol were also significantly higher in patients with T2DM than in the control group. In the patients with T2DM, serum betatrophin was positively correlated with age, FBS, TG, total cholesterol, and HbA1c. The results of this initial study in Iran have shown that circulating betatrophin levels are significantly increased in Iranian patients with T2DM compared with a control group. Additionally, it is postulated that betatrophin as a novel hormone may be involved in the generation of an atherogenic lipid profile.
Subject(s)
Humans , Adipose Tissue , Blood Glucose , Body Mass Index , Case-Control Studies , Cholesterol , Diabetes Mellitus , Diabetes Mellitus, Type 2 , Fasting , Glycated Hemoglobin , Insulin Resistance , Iran , Liver , TriglyceridesABSTRACT
Nanotechnology and nanoparticles are increasingly recognized for their potential applications in aerospace engineering, nanoelectronics, and environmental remediation, medicine and consumer products. More importantly is the potential for the application of silver nanoparticles [Ag NPs] in the treatment of diseases that require maintenance of circulating drug concentration or targeting of specific cells or organs the aim of this study was to investigate the possible protective role of Ag NP antioxidative biomarkers in rats. Ag NPs are used to investigate the potential risks for the environment and health. Rats received Ag NP, 5, 50, 250 and 500 mg/kg/day IP. After two week of treatment, the activity of enzymatic scavengers such as glutathione peroxidase [GPx], superoxide dismutase [SOD] and total antioxidant capacity [TAC] of blood samples were measured. Ag NP in 5, 50, 250 and 500 mg/kg reduced activities of CAT, SOD and increased TAC in plasma. In this study, Ag NP with 500mg/kg induced activities of CAT, SOD and decreased TAC. It is concluded that antioxidative properties of Ag NP is dose dependent